Get the Stockscreener App
8.62
1.49%
-0.13
After Hours:
8.62
Novavax Inc stock is traded at $8.62, with a volume of 3.58M.
It is down -1.49% in the last 24 hours and down -11.54% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
See More
Previous Close:
$8.75
Open:
$8.8
24h Volume:
3.58M
Relative Volume:
0.57
Market Cap:
$1.42B
Revenue:
$793.74M
Net Income/Loss:
$-398.71M
P/E Ratio:
-1.1873
EPS:
-7.26
Net Cash Flow:
$-514.43M
1W Performance:
+6.95%
1M Performance:
-11.54%
6M Performance:
-44.39%
1Y Performance:
+57.88%
1-Day Range:
$8.55
$9.03
1-Week Range:
$7.955
$9.49
52-Week Range:
$3.5324
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.62 | 1.42B | 793.74M | -398.71M | -514.43M | -7.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax and Assembly lead infectious disease gainers in 2024 - BioWorld Online
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls - AOL
Moderna Stock Jumps Following Bullish Sales View at Healthcare Conference - Investopedia
Is Biotech’s Bull Run Over? Examining Election Impacts - Investing.com
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell? - Yahoo! Voices
Novavax (STU:NVV1) 5-Year EBITDA Growth Rate : 1.20% (As of Sep. 2024) - GuruFocus.com
Novavax (STU:NVV1) Revenue per Share : €5.30 (TTM As of Sep. 2024) - GuruFocus.com
Novavax (HAM:NVV1) Price-to-Owner-Earnings : (As of Nov. 20, 2024) - GuruFocus.com
Menopause Treatment Market Opportunities, Challenges, - openPR
Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut - MSN
What is B. Riley's Estimate for Novavax FY2024 Earnings? - MarketBeat
Novavax to Present at Jefferies London Conference - TipRanks
Novavax in $123.8M settlement with U.K. agency over COVID vaccine deal - MSN
Preventive Vaccines Market May Set New Growth Story | Takeda - openPR
Health Care Flat After Last Week's SelloffHealth Care Roundup - Marketscreener.com
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
How To Trade (NVAX) - Stock Traders Daily
FY2024 Earnings Forecast for Novavax Issued By HC Wainwright - MarketBeat
Novavax Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Big Pharma Stocks Drop After RFK Jr. Announced as Health Secretary - Newsweek
UK regulator approves adapted Novavax jab - The Pharma Letter
Health stocks slide as Trump picks vaccine skeptic Kennedy - Los Angeles Times
Moderna, Novavax stocks slide after Trump nominates Robert F. Kennedy Jr. to be top health official - Yahoo Finance
Vaccine maker stocks fall after conspiracy theory-spreading RFK Jr. tapped to lead health department - New York Post
Shot Down: Vaccine stocks tumble with RFK Jr. as Health SecretaryFinbold - Finbold - Finance in Bold
Robert F. Kennedy Jr.’s Billion-Dollar Hit to Big Pharma - The New York Times
Health Stocks Slide as Trump Picks Vaccine Skeptic Kennedy - Yahoo Finance
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target - Simply Wall St
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary - Fast Company
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) - The Malaysian Reserve
Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS - Yahoo Finance
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill - Benzinga
Moderna, Novovax stocks slide after Trump nominates Robert F. Kennedy Jr. to be top health official - Yahoo Finance
Novavax, Inc. (NASDAQ:NVAX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
Trump Taps Vaccine Skeptic RFK Jr. to Lead HHS. Moderna, Novavax Stock Slide. - Barron's
Vaccine Maker Stocks Fall After Trump Taps RFK Jr. to Head HHS - MSN
Vaccine maker stocks tumble after Trump picks RFK Jr. for health secretary - CNN
Moderna, Novavax Shares Slip After Trump Names RFK Jr. Health Chief Nominee - Wall Street Pit
Big Pharma stocks tumble as Trump nominates RFK Jr. to lead HHS - The National Desk
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower - Benzinga
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data - Yahoo Finance
Novavax to Participate in Jefferies London Healthcare Conference - StreetInsider.com
Novavax Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Novavax Lowers 2024 Revenue Forecast Due To Weak Vaccine Sales - Finimize
Novavax (NVAX) Stock Experiences Significant Drop Amid Industry Volatility - GuruFocus.com
Protein-based Vaccine Sales Strategy Advances - Precision Vaccinations
Stock Market Increases While Tesla And Novavax Take A Hit - Finimize
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Trizzino John | EVP, CCO and CBO |
Aug 19 '24 |
Option Exercise |
0.00 |
655 |
0 |
28,627 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Aug 16 '24 |
Option Exercise |
12.96 |
2,367 |
30,676 |
15,652 |
| YOUNG JAMES F | Director |
Jun 21 '24 |
Sale |
14.09 |
7,500 |
105,675 |
61,760 |
| YOUNG JAMES F | Director |
Jun 18 '24 |
Sale |
13.72 |
7,500 |
102,881 |
69,260 |
| Dubovsky Filip | President, R&D |
Jun 17 '24 |
Option Exercise |
6.18 |
13,904 |
85,911 |
80,517 |
| Dubovsky Filip | President, R&D |
Jun 17 '24 |
Sale |
14.47 |
13,904 |
201,164 |
66,613 |
| MCGLYNN MARGARET G | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
10,470 |
| Alton Gregg H | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
10,470 |
| DOUGLAS RICHARD | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
43,920 |
| King Rachel K. | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
18,920 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):